NCT03452501View on ClinicalTrials.gov

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

CompletedOBSERVATIONAL
Enrollment

157

Participants

Timeline

Start Date

August 26, 2018

Primary Completion Date

August 17, 2020

Study Completion Date

August 17, 2020

Conditions
Inflammatory Bowel DiseasesCrohn DiseaseFistulizing Crohn's DiseaseUlcerative Colitis
Interventions
DRUG

Infliximab

A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg

Trial Locations (4)

11159

Prince Sultan Military Medical City, Riyadh

11426

King Abdullah International Medical Research Center, Riyadh

Unknown

King Abdulaziz University Hospital, Jeddah

King Saud Medical City, Riyadh

Sponsors
All Listed Sponsors
lead

Hikma Pharmaceuticals LLC

INDUSTRY